2024
DOI: 10.3390/cancers16193288
|View full text |Cite
|
Sign up to set email alerts
|

Measurable Residual Disease Testing in Multiple Myeloma Following T-Cell Redirecting Therapies

Kevin Guanwen Shim,
Rafael Fonseca

Abstract: Several novel T-cell-based therapies have recently become available for multiple myeloma (MM). These T-cell redirecting therapies (TRTs) include chimeric antigen receptor T-cells (CAR-T) and bispecific antibodies (BiAbs). In both clinical trial and real-world data, these therapies have demonstrated high rates of deep clinical response, and some are now approved for second-line treatment for relapsed MM. The deep and sustained clinical responses these therapies are capable of inducing will require sophisticated… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
references
References 126 publications
0
0
0
Order By: Relevance